Bird Flu (H5N1 Avian Influenza) VaccineThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

1492 records returned

Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses in Pre-Clinical StudiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Inovio's SynConTM Universal Flu Vaccines Provide 100% Protection in Ferrets against Death and Sickness in a Challenge Study with the Pandemic H1N1 Virus SAN DIEGO--(BUSINESS WIRE)--Nov 20, 2009 - Inovio Biomedical Corporation (NYSE Amex:INO), a... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 20, 2009 Category: Pharmaceuticals Source Type: clinical trials

The economy-wide impact of pandemic influenza on the UK: a computable general equilibrium modelling experimentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Balancing school closure against "business as usual" and obtaining sufficient stocks of effective vaccine are more important factors in determining the economic impact of an influenza pandemic than is the disease itself. Prophylactic absence from work in response to fear of infection can add considerably to the economic impact. (Source: BMJ Online First)
Source: BMJ Online First - November 20, 2009 Category: Journals (General) Authors: Smith, R. D, Keogh-Brown, M. R, Barnett, T., Tait, J. Tags: Infectious diseases, Epidemiologic studies, Immunology (including allergy) RESEARCH Source Type: journals

Potential economic impact of pandemic flu in the UKEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: BMJ Area: News Economic modelling suggests that pandemic flu could reduce UK gross domestic product (GDP) by between 0.5% (£8.4bn) and 4.3% (£73.2bn) or more, depending on the severity of the pandemic and on people's reaction; significant factors are whether schools are closed, and whether people choose prophylactic absence from work; adequate vaccination could reduce the maximum impact to about 1% of GDP. Pandemic flu would have both direct and indirect costs: this paper reports an attempt to model the indirect effect on the UK economy of pandemic flu according to various scenarios, including severit...
Source: NeLM - News - November 20, 2009 Category: Drugs & Pharmacology Source Type: organizations

Swine Flu Deception and Disinformation ExposedEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion - a recombinant strain produced from Bird Flu live viruses and a seasonal or Swine Flu strain can create a virus with morbidity (high widespread death rate).Last August, an international microbiologist in California, Joseph Moshe, called anti-vaccination activist Dr. A. True Ott, warning him of a bioweapon at Baxter's facilities in Ukraine that could be used to create a pandemic. Dr. Ott divulged this on Deagle's radio show after Moshe was forcefully apprehended.The Ukrainian IncidentUp until the 29th of October, there were only two non-lethal swine flu cases reported within Ukraine's 46 million population. Very...
Source: NaturalNews.com - November 19, 2009 Category: Consumer Health Advice Source Type: news

Swine flu vaccine uptakeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Several newspapers have reported that pregnant women and other vulnerable people are refusing to have the swine flu vaccine. The Times reported that a poll of GPs found that only 46% of people who were offered the vaccine have accepted it, and one doctor estimated that only 5% of pregnant women have had it. The news reports are based on a “snapshot” survey of 107 GPs. The survey asked how likely they were to hit the government’s target of vaccinating at least half of their patients who are under 65 and in high-risk groups this winter. GPs were also asked to estimate how many of the people who were offered the vacci...
Source: NHS News Feed - November 18, 2009 Category: Consumer Health News Tags: Swine flu Source Type: news

NOVAVAX Completes First Stage Of Enrollment In Pivotal H1N1 Influenza Vaccine Study In The Country Of MexicoEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Novavax, Inc. (Nasdaq: NVAX) announced that enrollment has been completed in the first stage of a two-stage clinical study of its novel 2009 H1N1 virus-like-particle (VLP) pandemic influenza unadjuvanted vaccine in the country of Mexico. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 17, 2009 Category: Consumer Health News Tags: Swine Flu Source Type: news

NOVAVAX Completes First Stage Of Enrollment In Pivotal H1N1 Influenza Vaccine Study In The Country Of MexicoEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Novavax, Inc. (Nasdaq: NVAX) announced that enrollment has been completed in the first stage of a two-stage clinical study of its novel 2009 H1N1 virus-like-particle (VLP) pandemic influenza unadjuvanted vaccine in the country of Mexico. An independent data and safety monitoring board has reviewed preliminary safety data from the first half of this cohort and recommended that this first stage continue as planned. (Source: Immune System / Vaccines News From Medical News Today)
Source: Immune System / Vaccines News From Medical News Today - November 17, 2009 Category: Allergy & Immunology Tags: Swine Flu Source Type: news

NOVAVAX Completes First Stage Of Enrollment In Pivotal H1N1 Influenza Vaccine Study In The Country Of MexicoEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Novavax, Inc. (Nasdaq: NVAX ) announced today that enrollment has been completed in the first stage of a two-stage clinical study of its novel 2009 H1N1 virus-like-particle (VLP) pandemic influenza unadjuvanted vaccine in the country of Mexico. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - November 16, 2009 Category: Pharmaceuticals Source Type: news

[Reflection and Reaction] Influenza vaccination of childrenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this issue of The Lancet Infectious Diseases, Rogier Bodewes and colleagues state that influenza vaccination is beneficial for infants and young children, but at the same time they urge re-evaluation of vaccine recommendations because the inactivated vaccine available at present does not induce heterosubtypic immunity and might make infants more susceptible to pandemic influenza. Although there are numerous immunological mechanisms related to infection with influenza to be discovered, we feel that the conclusions should be put into perspective. (Source: The Lancet Infectious Diseases)
Source: The Lancet Infectious Diseases - November 16, 2009 Category: Infectious Diseases Authors: Terho Heikkinen, Ville Peltola Tags: Reflection and Reaction Source Type: journals

[Personal View] Yearly influenza vaccinations: a double-edged sword?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Yearly vaccination against seasonal influenza viruses is recommended for certain individuals at high risk of complications associated with influenza. It has been recommended in some countries, including the USA, that all children aged 6–59 months are vaccinated against seasonal influenza. However, it has been shown—mainly in animals—that infection with influenza A viruses can induce protective immunity to influenza A viruses of other unrelated subtypes. This so-called heterosubtypic immunity does not provide full protection, but can limit virus replication and reduce morbidity and mortality of the host. This type of ...
Source: The Lancet Infectious Diseases - November 16, 2009 Category: Infectious Diseases Authors: Rogier Bodewes, Joost HCM Kreijtz, Guus F Rimmelzwaan Tags: Personal View Source Type: journals

Notes from the Field: Outbreak of 2009 Pandemic Influenza A (H1N1) Virus at a Large Public University in Delaware, April–May 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions. pH1N1 spread rapidly through the University of Delaware community with a surge in illness over a 2‐week period. Although initial cases appear to be associated with travel to Mexico, a rapid increase in cases was likely facilitated by increased student interactions during Greek Week. No protective effect from receiving seasonal influenza vaccine was identified. Although severe illness was rare, the outbreak caused a substantial burden and challenge to the university health care system. Preparedness efforts in universities and similar settings should include enhancing health care surge capacity. (Source: Cli...
Source: Clinical Infectious Diseases Latest Issue - November 13, 2009 Category: Infectious Diseases Tags: article MAJOR ARTICLE Source Type: journals

Economic Value of Seasonal and Pandemic Influenza Vaccination during PregnancyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions. Maternal influenza immunization is a highly cost‐effective intervention at disease rates and severity that correspond to both seasonal influenza epidemics and occasional pandemics. These findings justify ongoing efforts to optimize influenza vaccination during pregnancy from an economic perspective. (Source: Clinical Infectious Diseases Latest Issue)
Source: Clinical Infectious Diseases Latest Issue - November 13, 2009 Category: Infectious Diseases Tags: article MAJOR ARTICLE Source Type: journals

[News of the Week] Pandemic Influenza: Europe Reconsiders H1N1 Flu Shots for ChildrenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
As the H1N1 flu outbreak gathers speed and more vaccine becomes available, some European countries are now telling families that healthy children—or at least infants—are candidates for vaccination after all. The change of mind did not reassure a jittery public.Author: Martin Enserink (Source: Science: Current Issue)
Source: Science: Current Issue - November 13, 2009 Category: Science Authors: Martin Enserink Source Type: journals

Effectiveness of 2008--09 Trivalent Influenza Vaccine Against 2009 Pandemic Influenza A (H1N1) --- United States, May--June 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - November 13, 2009 Category: American Health Source Type: organizations

Antibody reactivity of conformational peptide mimics of a conserved H5N1 neutralization site in different fusion proteinsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, the secondary and possibly higher structural orders of the peptide mimics 122 and 125 were investigated and found to be closely related to the specific binding with 8H5 mAb. These two peptide mimics were fused to three different carrier proteins, and the antibody binding activities were recovered in 4 of the 11 fusion proteins. HEV structural protein p239 and HBc were more suitable than the outer membrane protein T47 of the Treponema pallidum particle for the recovery of reactivity. The increase in the copy number of peptide mimics was important for the recovery of antibody-binding activity and the inter...
Source: Archives of Virology - November 13, 2009 Category: Virology Tags: Archives of Virology Source Type: journals

Anti-viral properties and mode of action of standardized Echinacea purpurea extract against highly pathogenic avian Influenza virus (H5N1, H7N7) and swine-origin H1N1 (S-OIV)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: As a result of these investigations, we believe that this standard Echinacea preparation, used at the recommended dose for oral consumption, could be a useful, readily available and affordable addition to existing control options for IV replication and dissemination. (Source: Virology Journal)
Source: Virology Journal - November 13, 2009 Category: Virology Authors: Stephan PleschkaMichael SteinRoland SchoopJames Hudson Source Type: journals

Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States, May-June 2009.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Authors: Since first reports in April 2009, the 2009 pandemic influenza A (H1N1) virus has spread around the world. The pandemic virus is antigenically distinct from seasonal influenza A (H1N1) viruses targeted by seasonal influenza vaccines. Results from recent serologic studies have suggested that seasonal influenza vaccines are unlikely to provide substantial cross-protection against infection with the pandemic H1N1 virus. However, how serologic results correlate with the complex immune responses that confer clinical protection remains uncertain. To complement the serologic studies and evaluate the effectiveness o...
Source: MMWR Morb Mortal Wkl... - November 13, 2009 Category: Epidemiology Tags: MMWR Morb Mortal Wkly Rep Source Type: journals

CSL Biotherapies Obtains FDA Licensure For Use Of Its Thimerosal-Free Pandemic Influenza A (H1N1) 2009 Monovalent Vaccine In ChildrenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CSL Biotherapies, a subsidiary of CSL Limited (ASX: CSL), one of the world's leading manufacturers of influenza vaccine, announced that the U.S. Food and Drug Administration (FDA) has approved the company's application for accelerated approval of its seasonal flu vaccine, Afluria® (Influenza Virus Vaccine) for use in the pediatric population aged 6 months and older. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 12, 2009 Category: Consumer Health News Tags: Swine Flu Source Type: news

CSL Biotherapies Obtains FDA Licensure For Use Of Its Thimerosal-Free Pandemic Influenza A (H1N1) 2009 Monovalent Vaccine In ChildrenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CSL Biotherapies, a subsidiary of CSL Limited (ASX: CSL), one of the world's leading manufacturers of influenza vaccine, announced that the U.S. Food and Drug Administration (FDA) has approved the company's application for accelerated approval of its seasonal flu vaccine, Afluria® (Influenza Virus Vaccine) for use in the pediatric population aged 6 months and older. (Source: Immune System / Vaccines News From Medical News Today)
Source: Immune System / Vaccines News From Medical News Today - November 12, 2009 Category: Allergy & Immunology Tags: Swine Flu Source Type: news

A Live Attenuated H1N1 M1 Mutant Provides Broad Cross‐Protection against Influenza A Viruses, Including Highly Pathogenic A/Vietnam/1203/2004, in MiceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Journal of Infectious Diseases, Volume 0, Issue 0, Page 000, Latest Articles. The emergence of novel influenza A H1N1 and highly pathogenic avian influenza (HPAI) H5N1 viruses underscores the urgency of developing efficient vaccines against an imminent pandemic. M(NLS‐88R) (H1N1), an A/WSN/33 mutant with modifications in the multibasic motif 101RKLKR105 of the matrix (M1) protein and its adjacent region, was generated by reverse genetics. The M(NLS‐88R) mutant had in vitro growth characteristics similar to those of wild‐type A/WSN/33 (wt‐WSN), but it was attenuated in mice. Vaccination with M(NLS‐88R) n...
Source: The Journal of Infectious Diseases Latest Issue - November 12, 2009 Category: Infectious Diseases Tags: article MAJOR ARTICLE Source Type: journals

Pandemic 2009 Influenza Update: Pandemrix™ Data On Co Administration With Annual Seasonal Influenza Vaccine (Fluarix®)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
GlaxoSmithKline (GSK) announced the results from the clinical trial assessing Pandemrix™, GSK's adjuvanted H1N1 pandemic influenza vaccine, administered at the same time as the annual seasonal influenza vaccine, Fluarix ®. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 12, 2009 Category: Consumer Health News Tags: Swine Flu Source Type: news

Pandemic 2009 Influenza Update: Pandemrix™ Data On Co Administration With Annual Seasonal Influenza Vaccine (Fluarix®)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
GlaxoSmithKline (GSK) announced the results from the clinical trial assessing Pandemrix™, GSK's adjuvanted H1N1 pandemic influenza vaccine, administered at the same time as the annual seasonal influenza vaccine, Fluarix ®. The trial showed that co-administration of one dose of both vaccines in separate arms, induced a strong response in adults for both the H1N1 pandemic vaccine as well as the seasonal vaccine. (Source: Pharma Industry News From Medical News Today)
Source: Pharma Industry News From Medical News Today - November 12, 2009 Category: Pharmaceuticals Tags: Swine Flu Source Type: news

GSK announces trial data on co-administration of PandemrixT with annual seasonal influenza vaccine (Fluarix®)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: PharmaLive Area: News GlaxoSmithKline (GSK) has announced the results from the trial assessing PandemrixT, its adjuvanted H1N1 pandemic influenza vaccine, administered at the same time as the annual seasonal influenza vaccine, Fluarix®. The trial involves 168 adults aged over 60 years of age and showed that 89.3% of the subjects receiving both vaccines at the same time demonstrated a response for the H1N1 virus that was above the regulatory threshold of 1:40 seroprotection considered indicative of protection. The immune response for the seasonal vaccine exceeded the regulatory threshold defined by inte...
Source: NeLM - Immunology and vaccination - November 10, 2009 Category: Allergy & Immunology Source Type: organizations

Pandemic 2009 Influenza Update: Pandemrix data on co-administration with annual seasonal influenza vaccine (Fluarix)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
LONDON, Nov. 9, 2009- GlaxoSmithKline (GSK) today announced the results from the clinical trial assessing Pandemrix™, GSK’s adjuvanted H1N1 pandemic influenza vaccine, administered at the same time as the annual seasonal... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 9, 2009 Category: Pharmaceuticals Source Type: clinical trials

Pandemic 2009 Influenza Update: Pandemrix™ data on co-administration with annual seasonal influenza vaccine (Fluarix®)sEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
GlaxoSmithKline (GSK) today announced the results from the clinical trial assessing Pandemrix™, GSK’s adjuvanted H1N1 pandemic influenza vaccine, administered at the same time as the annual seasonal influenza vaccine, Fluarix ®. (Source: GSK news)
Source: GSK news - November 9, 2009 Category: Pharmaceuticals Source Type: organizations

Amelioration of pneumonia with Streptococcus pneumoniae infection by inoculation with a vaccine against highly pathogenic avian influenza virus in a non-human primate mixed infection modelEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Vaccination against HPAIV reduces pneumonia caused by bacterial superinfection and may improve prognosis of HPAIV-infected patients. (Source: Journal of Medical Primatology)
Source: Journal of Medical Primatology - November 9, 2009 Category: Research Authors: Taichiro Miyake, Kosuke Soda, Yasushi Itoh, Yoshihiro Sakoda, Hirohito Ishigaki, Tomoya Nagata, Hideaki Ishida, Misako Nakayama, Hiroichi Ozaki, Hideaki Tsuchiya, Ryuzo Torii, Hiroshi Kida, Kazumasa Ogasawara Source Type: journals

The 2009 pandemic H1N1 influenza and indigenous populations of the Americas and the Pacific.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
There are few structured data available to assess the risks associated with pandemic influenza A(H1N1)v infection according to ethnic groups. In countries of the Americas and the Pacific where these data are available, the attack rates are higher in indigenous populations, who also appear to be at approximately three to six-fold higher risk of developing severe disease and of dying. These observations may be associated with documented risk factors for severe disease and death associated with pandemic H1N1 influenza infection (especially the generally higher prevalence of diabetes, obesity, asthma, chronic obstructive ...
Source: Euro Surveill - November 6, 2009 Category: Infectious Diseases Authors: La Ruche G, Tarantola A, Barboza P, Vaillant L, Gueguen J, Gastellu-Etchegorry M, Tags: Euro Surveill Source Type: journals

Use of an inactivated vaccine in mitigating pandemic influenza A(H1N1) spread: a modelling study to assess the impact of vaccination timing and prioritisation strategies.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The impact of prioritization and of timing of vaccination strategies on reducing transmission of pandemic influenza A(H1N1) was evaluated in a community with the structure of the Greek population using a stochastic simulation model. Prioritization scenarios were based on the recommendations of the United States Centers for Disease Control and Prevention Advisory Committee on Immunization Practices and vaccination was assumed to initiate either before or during the ongoing epidemic. In the absence of intervention, an illness attack rate (AR) of 34.5% is anticipated. Vaccinating the priority groups before the epidemic (p...
Source: Euro Surveill - November 6, 2009 Category: Infectious Diseases Authors: Sypsa V, Pavlopoulou I, Hatzakis A Tags: Euro Surveill Source Type: journals

Pandemic H1N1 influenza: predicting the course of a pandemic and assessing the efficacy of the planned vaccination programme in the United States.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We use data on confirmed cases of pandemic influenza A(H1N1), disseminated by the United States Centers for Disease Control and Prevention(US CDC), to fit the parameters of a seasonally forced Susceptible, Infective, Recovered (SIR) model. We use the resulting model to predict the course of the H1N1 influenza pandemic in autumn 2009, and we assess the efficacy of the planned CDC H1N1 vaccination campaign. The model predicts that there will be a significant wave in autumn, with 63% of the population being infected, and that this wave will peak so early that the planned CDC vaccination campaign will likely not have a lar...
Source: Euro Surveill - November 6, 2009 Category: Infectious Diseases Authors: Towers S, Feng Z Tags: Euro Surveill Source Type: journals

Pandemic influenza A(H1N1) 2009 vaccines in the European Union.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Pandemic vaccines from four manufacturers are now available for use within the European Union (EU). Use of these vaccines will protect individuals and reduce the impact on health services to more manageable levels. The majority of the severely ill will be from known risk groups and the best strategy will be to start vaccinating in line with the recommendation from the European Union Health Security Committee prioritizing adults and children with chronic conditions, pregnant women and healthcare workers. The composition of authorized vaccines is reviewed in this article. The vaccine strain in all authorized pandemic vac...
Source: Euro Surveill - November 6, 2009 Category: Infectious Diseases Authors: Johansen K, Nicoll A, Ciancio BC, Kramarz P Tags: Euro Surveill Source Type: journals

"I-MOVE" towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, 2008-9Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Within I-MOVE (European programme to monitor seasonal and pandemic influenza vaccine effectiveness (IVE)) five countries conducted IVE pilot case-control studies in 2008-9. One hundred and sixty sentinel general practitioners (GP) swabbed all elderly consulting for influenza-like illness (ILI). Influenza confirmed cases were compared to influenza negative controls. We conducted a pooled analysis to obtain a summary IVE in the age group of ?65 years. We measured IVE in each study and assessed heterogeneity between studies qualitatively and using the I2 index. We used a one-stage pooled model with study as a fixed effect. W...
Source: Eurosurveillance latest news - November 5, 2009 Category: Infectious Diseases Source Type: journals

Experts Advise WHO on Pandemic Vaccine Policies and StrategiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Strategic Advisory Group of Experts (SAGE) on Immunization, which advises WHO on policies and strategies for vaccines and immunization, devoted a session of its 27–29 October meeting to pandemic influenza vaccines. (Source: PandemicFlu.gov RSS Feed for News Releases)
Source: PandemicFlu.gov RSS Feed for News Releases - November 3, 2009 Category: American Health Source Type: news

Pneumonia vaccine could save money in flu pandemicEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CHICAGO (Reuters) - A more protective form of Pfizer's vaccine for pneumococcal disease would be highly effective at preventing deaths from pandemic influenza, independent researchers and the company reported over the weekend. (Source: Reuters: Health)
Source: Reuters: Health - November 2, 2009 Category: Consumer Health News Tags: healthNews Source Type: news

WHO backs one-dose regimen for pandemic influenza vaccineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Read the full story on MD Consult: WHO backs one-dose regimen for pandemic influenza vaccine (Source: MD Consult: News: Top Stories)
Source: MD Consult: News: Top Stories - November 2, 2009 Category: Journals (General) Source Type: info

Experts Advise WHO On Pandemic Vaccine (H1N1) Policies And StrategiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Strategic Advisory Group of Experts (SAGE) on Immunization, which advises WHO (World Health Organization) on policies and strategies for vaccines and immunization, devoted a session of its 27-29 October meeting to pandemic influenza vaccines. The experts reviewed the current epidemiological situation of the pandemic worldwide and considered issues and options from a public health perspective. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 1, 2009 Category: Consumer Health News Tags: Swine Flu Source Type: news

Parents Not Keen on H1N1 Vaccine for ChildrenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Despite clinical evidence suggesting that children are at higher risk for pandemic influenza A(H1N1) complications, only 40% of parents surveyed said they plan to have their children vaccinated against that strain of the flu. (Source: Skin and Allergy News)
Source: Skin and Allergy News - November 1, 2009 Category: Dermatology Authors: MICHELE G. SULLIVAN Tags: Infectious Diseases Source Type: journals

CDC Officials Continue to Urge Priority Groups to Receive Pandemic Flu VaccineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Vaccination for the pandemic influenza A(H1N1) virus remains critical, because it is medicine's best tool for preventing or moderating infection, officials with the Centers for Disease Control and Prevention continued to stress last month. (Source: Skin and Allergy News)
Source: Skin and Allergy News - November 1, 2009 Category: Dermatology Authors: MITCHEL L. ZOLER Tags: Infectious Diseases Source Type: journals

H1N1 Vaccine Production Hiccups Impair Distribution: Illness net rates are highest in 6 years.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A hiccup in manufacturing production has caused delays in distributing the vaccine for the pandemic influenza A(H1N1) virus, Health and Human Services Secretary Kathleen Sebelius testified during a hearing of the Senate Committee on Homeland Security and Governmental Affairs. (Source: Family Practice News)
Source: Family Practice News - November 1, 2009 Category: Primary Care Authors: DOUG BRUNK Tags: News Source Type: news

U.S. Government Foots H1N1 Vaccination BillEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The U.S. government has picked up most of the tab for its aggressive campaign to get vaccine against pandemic influenza A(H1N1) into a majority of its residents, spending more than $6 billion in the process. (Source: Family Practice News)
Source: Family Practice News - November 1, 2009 Category: Primary Care Authors: MITCHEL L. ZOLER Tags: Infectious Diseases Source Type: news

Pandemic Flu Vaccine Under Study for AsthmaticsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A new phase II trial will test the safety and efficacy of the pandemic influenza A(H1N1) vaccine on patients with mild to severe asthma. Although the vaccine has already been approved as safe and effective in the general population, additional studies are necessary to confirm its effect on those with asthma—especially those who take glucocorticoid medications, Dr. Anthony Fauci said in a statement. (Source: Family Practice News)
Source: Family Practice News - November 1, 2009 Category: Primary Care Authors: MICHELE G. SULLIVAN Tags: Pulmonary Medicine Source Type: news

Neurologists Are Urged to Report New-Onset GBSEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Neurologists should be on the lookout this fall and winter for new cases of Guillain-Barré Syndrome, which could be related to the pandemic influenza A(H1N1) vaccine. The Centers for Disease Control and Prevention and the American Academy of Neurology are asking neurologists to report any new cases of Guillain-Barré (GBS) following pandemic flu vaccination to the national Vaccine Adverse Event Reporting System (VAERS). (Source: Clinical Neurology News)
Source: Clinical Neurology News - November 1, 2009 Category: Neurology Authors: MICHELE G. SULLIVAN Tags: News Source Type: news

Should health care workers be required to be immunized against influenza?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Ms. Nutty is president of the Association for Professionals in Infection Control and Epidemiology. The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices provides annual recommendations for prevention of influenza by vaccination. ACIP currently recommends vaccination against both seasonal influenza and the pandemic influenza A(H1N1) virus when vaccines become available. Because of their close proximity to sick people, health care workers are among the priority groups to receive both vaccines. (Source: Clinical Psychiatry News)
Source: Clinical Psychiatry News - November 1, 2009 Category: Psychiatry Authors: CHRISTINE J. NUTTY, TINA GERARDI Tags: Point/Counterpoint Source Type: journals

Experts advise WHO on pandemic vaccine policies and strategiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Strategic Advisory Group of Experts (SAGE) on Immunization, which advises WHO on policies and strategies for vaccines and immunization, devoted a session of its 27–29 October meeting to pandemic influenza vaccines. The experts reviewed the current epidemiological situation of the pandemic worldwide and considered issues and options from a public health perspective. (Source: WHO Swine Flu)
Source: WHO Swine Flu - October 30, 2009 Category: Infectious Diseases Source Type: organizations

Primary Medical Services (Directed Enhanced Services - Pandemic Influenza (H1N1) Vaccination Scheme) and Statement of Financial Entitlements (Amendment) (No. 6) Directions 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: Department of Health (DH) Area: News These Directions come into force from 30th October and require PCTs to offer to enter into a Directed Enhanced Service with their existing primary medical care contractors who hold a list of registered patients, by 13th November, to deliver the H1N1 vaccine to patients in the priority groups identified in the CMO letter of 13 August 2009. (Source: NeLM - Immunology and vaccination)
Source: NeLM - Immunology and vaccination - October 30, 2009 Category: Allergy & Immunology Source Type: organizations

Profit Driven Swine Flu Propaganda - Pump Up the Volume - Part FourEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This article is part four in a six-part series. Be sure to read part three at http://www.naturalnews.com/027310_swine_flu_health_Tamiflu.htmlThose in control of the mainstream media have joined together with public health officials to provide the pharmaceutical industry with the best swine flu promotional campaign that money can buy.In an October 7, 2009, OpEd News article titled, "The Centers for Disease Control: The Best Vaccination PR Firm Taxes Can Buy," the makers of the documentaries, "Vaccine Nation," and "Autism: Made in the USA," Richard Gale and Dr Gary Null wrote: "If the flu season goes according to schedule, t...
Source: NaturalNews.com - October 27, 2009 Category: Consumer Health Advice Source Type: news

Pandemrix® H1N1 (swine flu) vaccine effective in children after one dose?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: Department of Health (DH) Area: News According to a Reuters report, GlaxoSmithKline said that early results from a study of its Pandemrix® pandemic influenza vaccine have shown that it was effective after just one dose in all of the 200 children (aged 6-36 months) tested. Following advice from the Joint Committee on Vaccination and Immunisation, a two-dose schedule of Pandemrix® is currently recommended for children aged from 6 months of age to less than 10 years of age (see link below to view DoH information sheet). (Source: NeLM - Immunology and vaccination)
Source: NeLM - Immunology and vaccination - October 26, 2009 Category: Allergy & Immunology Source Type: organizations

Sinovac Receives Certificate Of Approval To Distribute PANFLU.1 (H1N1) In MexicoEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, today announced that it has received a Certificate of Approval from the Secretaria de Salud to distribute PANFLU.1, its H1N1 pandemic influenza (swine flu) vaccine, in Mexico. The certificate is valid through October 13, 2014. Laboratorios Imperiales S.A. de C.V. (Source: Pharma Industry News From Medical News Today)
Source: Pharma Industry News From Medical News Today - October 23, 2009 Category: Pharmaceuticals Tags: Swine Flu Source Type: news

Tips from the journals of the American Society for MicrobiologyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(American Society for Microbiology) The following are tips from the Journals of the American Society for Microbiology: "Genes May Determine Susceptibility to H5N1 Avian Influenza A Virus Infection"; "Cigarette Smoke May Impair Lungs Natural Defense Against Harmful Pathogen"; and "T-Cell Vaccine Reduces Simian Immunodeficiency Virus Levels in Semen of Monkeys During Primary Infection." (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - October 23, 2009 Category: Global & Universal Source Type: news

Possible hidden hazards of mass vaccination against new influenza A/H1N1: have the cardiovascular risks been adequately weighed?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Programs for vaccination against the new influenza A/H1N1 targeting many hundred million citizens in Europe and the USA are to be launched in the fall of this year. The USA is planning to employ a non-adjuvanted vaccine, whereas European nations are opting for inclusion of MF59, the adjuvant contained in an alternative seasonal flu vaccine, or the related adjuvant AS03 that is contained in a recently developed H5N1 vaccine. We draw attention to unappreciated hazards of using adjuvanted vaccine in Europe. Evidence from animal experiments in conjunction with clinical epidemiological data indicates tha...
Source: Medical Microbiology and Immunology - October 22, 2009 Category: Microbiology Tags: Medical Microbiology and Immunology Source Type: journals

Dr. Weil was right: Astragalus herb really helps fight the flu (influenza)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(NaturalNews) The FTC and FDA are terrorizing Dr. Andrew Weil over his true statements about the immune-boosting properties of astragalus. According to the FDA, astragalus has no antiviral or antibacterial properties whatsoever and is of absolutely no use in the human body. Sound bizarre?I thought so too. That's why I asked NaturalNews researchers to assemble a collection of statements in support of Dr. Weil's astragalus statements. This medicinal herb does, indeed, boost healthy immune function and offer protection against influenza. And because it's a multifaceted, complex plant-based medicine, it's not outsmarted by one...
Source: NaturalNews.com - October 22, 2009 Category: Consumer Health Advice Source Type: news